[ CAS No. 175278-11-2 ] {[proInfo.proName]}

Name: 175278-11-2|1-Bromo-3,5-difluoro-2-iodobenzene|97%
Brand: Ambeed
SKU: A172305
Price: 9.0 USD
Availability: InStock
Rating: 91 (26 reviews)

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

DV 2D 3D

3d Animation Molecule Structure of 175278-11-2

Structure of 175278-11-2 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 175278-11-2 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 175278-11-2 ]

SDS Specification

Alternatived Products of [ 175278-11-2 ]

Product Details of [ 175278-11-2 ]

CAS No. :	175278-11-2	MDL No. :	MFCD00042183
Formula :	C₆H₂BrF₂I	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	KJJGFGWQNCPZBG-UHFFFAOYSA-N
M.W :	318.89	Pubchem ID :	519447
Synonyms :

Calculated chemistry of [ 175278-11-2 ]

Physicochemical Properties

Num. heavy atoms :	10
Num. arom. heavy atoms :	6
Fraction Csp3 :	0.0
Num. rotatable bonds :	0
Num. H-bond acceptors :	2.0
Num. H-bond donors :	0.0
Molar Refractivity :	46.77
TPSA :	0.0 Å²

Pharmacokinetics

GI absorption :	Low
BBB permeant :	Yes
P-gp substrate :	No
CYP1A2 inhibitor :	Yes
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-5.79 cm/s

Lipophilicity

Log Po/w (iLOGP) :	2.33
Log Po/w (XLOGP3) :	3.46
Log Po/w (WLOGP) :	4.17
Log Po/w (MLOGP) :	4.78
Log Po/w (SILICOS-IT) :	4.34
Consensus Log Po/w :	3.82

Druglikeness

Lipinski :	1.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	1.0
Bioavailability Score :	0.55

Water Solubility

Log S (ESOL) :	-4.44
Solubility :	0.0116 mg/ml ; 0.0000362 mol/l
Class :	Moderately soluble
Log S (Ali) :	-3.14
Solubility :	0.23 mg/ml ; 0.000722 mol/l
Class :	Soluble
Log S (SILICOS-IT) :	-4.74
Solubility :	0.00584 mg/ml ; 0.0000183 mol/l
Class :	Moderately soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	3.0 alert
Leadlikeness :	0.0
Synthetic accessibility :	2.39

Safety of [ 175278-11-2 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P261-P305+P351+P338	UN#:	N/A
Hazard Statements:	H315-H319-H335	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 175278-11-2 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 175278-11-2 ]

[ 175278-11-2 ] Synthesis Path-Downstream 1~59

1
[ 175278-11-2 ]
[ 1400978-02-0 ]

Reference： [1]Journal of Medicinal Chemistry,2012,vol. 55,p. 9346 - 9361,16

2
[ 175278-11-2 ]
[ 1400977-98-1 ]

Reference： [1]Journal of Medicinal Chemistry,2012,vol. 55,p. 9346 - 9361,16

3
[ 175278-11-2 ]
[ 1400977-99-2 ]

Reference： [1]Journal of Medicinal Chemistry,2012,vol. 55,p. 9346 - 9361,16

4
[ 175278-11-2 ]
[ 1400978-00-8 ]

Reference： [1]Journal of Medicinal Chemistry,2012,vol. 55,p. 9346 - 9361,16

5
[ 175278-11-2 ]
[ 1400978-01-9 ]

Reference： [1]Journal of Medicinal Chemistry,2012,vol. 55,p. 9346 - 9361,16

6
[ 175278-11-2 ]
[ 1337606-50-4 ]

Reference： [1]Journal of Medicinal Chemistry,2012,vol. 55,p. 9346 - 9361,16
[2]Patent: US2015/126449,2015,A1
[3]Patent: WO2015/67549,2015,A1

7
[ 175278-11-2 ]
[ 1400977-81-2 ]

Reference： [1]Journal of Medicinal Chemistry,2012,vol. 55,p. 9346 - 9361,16

8
[ 175278-11-2 ]
[ 1400977-82-3 ]

Reference： [1]Journal of Medicinal Chemistry,2012,vol. 55,p. 9346 - 9361,16

9
[ 175278-11-2 ]
N-((2-cyano-3,5-difluorophenyl)-(2-(difluoromethyl)-4-pyridyl)methylene)-2-methylpropane-2-sulfinamide [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2012,vol. 55,p. 9346 - 9361,16

10
[ 175278-11-2 ]
[ 1400977-84-5 ]

Reference： [1]Journal of Medicinal Chemistry,2012,vol. 55,p. 9346 - 9361,16

11
[ 175278-11-2 ]
[ 1400977-85-6 ]

Reference： [1]Journal of Medicinal Chemistry,2012,vol. 55,p. 9346 - 9361,16

12
[ 175278-11-2 ]
[ 1400977-86-7 ]

Reference： [1]Journal of Medicinal Chemistry,2012,vol. 55,p. 9346 - 9361,16

13
2-formylmorpholine [ No CAS ]
[ 175278-11-2 ]
[ 154650-59-6 ]

Reference： [1]Journal of Medicinal Chemistry,2012,vol. 55,p. 9346 - 9361,16

14
[ 175278-11-2 ]
4-bromo-6-fluoro-1H-indazol-3-amine [ No CAS ]

Reference： [1]Patent: US2015/126449,2015,A1
[2]Patent: WO2015/67549,2015,A1

15
[ 175278-11-2 ]
tert-butyl 4-(10-bromo-8-fluoro-2-oxo-1,2-dihydropyrimido[1,2-b]indazol-4-yl)piperidine-1-carboxylate [ No CAS ]

Reference： [1]Patent: US2015/126449,2015,A1
[2]Patent: WO2015/67549,2015,A1

16
[ 4394-85-8 ]
[ 175278-11-2 ]
[ 154650-59-6 ]

Yield	Reaction Conditions	Operation in experiment
2.70 g		Example 133A 2-Bromo-4,6-difluorobenzaldehyde 1-Bromo-3,5-difluoro-2-iodobenzene (5.00 g, 15.7 mmol) was dissolved in 2-methyltetrahydrofuran (30 mL) and cooled to 0 C. Isopropylmagnesium chloride lithium chloride complex (1.3 M in tetrahydrofuran, 12.7 mL, 16.5 mmol) was added dropwise. After stirring at 0 C. for 30 min, 4-formylmorpholine (1.99 g, 17.2 mmol) was added. The mixture was warmed to RT and stirred at RT for 4 h. The mixture was quenched with hydrochloric acid (1M in water), diluted with water, and extracted with ethyl acetate. The organic phase was washed with hydrochloric acid (1M in water), water, and brine, and dried over magnesium sulfate. Concentration in vacuo afforded the title compound (2.70 g, 70% of theory) in a purity of 92%. GC-MS (Method 1G): Rt=3.37 min, MS (ESIPos): m/z=219 [M+H]+
		l-Bromo-3,5-difluoro-2-iodobenzene (5.00 g, 15.7 mmol) was dissolved in 2-methyltetrahydrofuran (30 mL) and cooled to 0 C. Isopropylmagnesium chloride lithium chloride complex (1.3 M in tetrahydroiuran, 12.7 mL, 16.5 mmol) was added dropwise. After stirring at 0 C for 30 min, 4- formylmorpholine (1.99 g, 17.2 mmol) was added. The mixture was warmed to RT and stirred at RT for 4 h. The mixture was quenched with hydrochloric acid (IM in water), diluted with water, and extracted with ethyl acetate. The organic phase was washed with hydrochloric acid (IM in water), water, and brine, and dried over magnesium sulfate. Concentration in vacuo afforded the title compound (2.70 g, 70% of theory) in a purity of 92%. GC-MS (Method 1G): Rt = 3.37 min, MS (ESIPos): m/z = 219 [M+H]+

Reference： [1]Patent: US2015/126449,2015,A1 .Location in patent: Paragraph 0746 - 0748
[2]Patent: WO2015/67549,2015,A1 .Location in patent: Page/Page column 133

17
[ 175278-11-2 ]
10-bromo-8-fluoro-4-(piperidin-4-yl)pyrimido[1,2-b]indazol-2(1H)-one hydrochloride [ No CAS ]

Reference： [1]Patent: WO2015/67549,2015,A1

18
[ 1166829-70-4 ]
[ 175278-11-2 ]
ethyl 2-(2’-bromo-4’,6’-difluoro-2,3,4,5-tetrahydro-[1,1‘-biphenyl]-4-yl)acetate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
86%	With (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; sodium carbonate; In 1,4-dioxane; at 70℃; for 20h;Sealed tube;	Step 3. Ethyl 2-(2'-bromo-4',6'-difluoro-2,3,4,5-tetrahydro-[l,l'-biphenyl]-4-yl)acetate. In a sealed microwave tube, a mixture of ethyl 2-[4-(tetramethyl-l,3,2-dioxaborolan-2- yl)cyclohex-3-en-l-yl] acetate (200 mg, 0.68 mmol), [1,1'- bis(diphenylphosphino)ferrocene]dichloropalladium(II) (24.9 mg, 0.03 mmol), l-bromo-3,5- difluoro-2-iodobenzene (260 mg, 0.82 mmol) and sodium carbonate (0.85 mL, 2.0 M, 1.7 mmol) in dioxane (3.40 mL) was heated at 70C for 20 h. Upon completion of the reaction, the reaction mixture was filtered through celite, washed thoroughly with EtOAc, and purified via flash chromatography (0-20% EtOAc/heptanes) to obtain the title compound as a colorless oil (210 mg, 86%). 1H NMR (400 MHz, CDCb) d 7.13 (td, /= 2.0, 8.1 Hz, 1H), 6.78 (dt, / = 2.5, 8.8 Hz, 1H), 5.60 (d, / = 1.7 Hz, 1H), 4.17 (q, / = 7.2 Hz, 2H), 2.45 - 2.31 (m, 3H), 2.22 - 2.12 (m, 1H), 2.00 - 1.84 (m, 2H), 1.63 - 1.50 (m, 1H), 1.48 (s, 2H), 1.28 (t, / = 7.1 Hz, 3H). [M+H] = 361.0.

Reference： [1]Patent: WO2019/168866,2019,A1 .Location in patent: Page/Page column 99

19
[ 175278-11-2 ]
2-[4-(2,4-difluoro-6-methylphenyl)cyclohexyl]ethan-1-ol [ No CAS ]

Reference： [1]Patent: WO2019/168866,2019,A1

20
[ 175278-11-2 ]
ethyl 2-(2’,4’-difluoro-6’-methyl-2,3,4,5-tetrahydro-[1,1'-biphenyl]-4-yl)acetate [ No CAS ]

Reference： [1]Patent: WO2019/168866,2019,A1

21
[ 175278-11-2 ]
ethyl 2-(4-(2,4-difluoro-6-methylphenyl)cyclohexyl)acetate [ No CAS ]

Reference： [1]Patent: WO2019/168866,2019,A1

22
[ 201230-82-2 ]
[ 175278-11-2 ]
[ 501-65-5 ]
[ 1380243-13-9 ]

Reference： [1]Advanced Synthesis and Catalysis,2019,vol. 361,p. 5521 - 5527

23
[ 175278-11-2 ]
3-(2-bromo-4,6-difluorophenyl)-2-methylpropan-1-ol [ No CAS ]

Reference： [1]Patent: WO2020/47207,2020,A1

24
[ 175278-11-2 ]
5-bromo-7-fluoro-3-methylchromane [ No CAS ]

Reference： [1]Patent: WO2020/47207,2020,A1

25
[ 175278-11-2 ]
tert-butyl 2-(7-fluoro-3-methylchroman-5-yl)acetate [ No CAS ]

Reference： [1]Patent: WO2020/47207,2020,A1

26
[ 175278-11-2 ]
tert-butyl 2-bromo-2-(7-fluoro-3-methylchroman-5-yl)acetate [ No CAS ]

Reference： [1]Patent: WO2020/47207,2020,A1

27
[ 175278-11-2 ]
tert-butyl 2-(7-fluoro-3-methylchroman-5-yl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetate [ No CAS ]

Reference： [1]Patent: WO2020/47207,2020,A1

28
[ 175278-11-2 ]
2-(7-fluoro-3-methylchroman-5-yl)-2-((R)-3-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetic acid [ No CAS ]

Reference： [1]Patent: WO2020/47207,2020,A1

29
[ 175278-11-2 ]
3-(2-bromo-4,6-difluorobenzyl)-2-methylbut-3-en-2-ol [ No CAS ]

Reference： [1]Patent: WO2020/47207,2020,A1

30
[ 175278-11-2 ]
2-(2-bromo-4,6-difluorobenzyl)-3-methylbutane-1,3-diol [ No CAS ]

Reference： [1]Patent: WO2020/47207,2020,A1

31
[ 175278-11-2 ]
2-(5-bromo-7-fluorochroman-3-yl)propan-2-ol [ No CAS ]

Reference： [1]Patent: WO2020/47207,2020,A1

32
[ 175278-11-2 ]
5-bromo-7-fluoro-3-(2-fluoropropan-2-yl)chromane [ No CAS ]

Reference： [1]Patent: WO2020/47207,2020,A1

33
[ 175278-11-2 ]
tert-butyl 2-(7-fluoro-3-(2-fluoropropan-2-yl)chroman-5-yl)acetate [ No CAS ]

Reference： [1]Patent: WO2020/47207,2020,A1

34
[ 175278-11-2 ]
tert-butyl 2-bromo-2-(7-fluoro-3-(2-fluoropropan-2-yl)chroman-5-yl)acetate [ No CAS ]

Reference： [1]Patent: WO2020/47207,2020,A1

35
[ 175278-11-2 ]
tert-butyl 2-(7-fluoro-3-(2-fluoropropan-2-yl)chroman-5-yl)-2-((R)-3-(4-(4-methoxy-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetate [ No CAS ]

Reference： [1]Patent: WO2020/47207,2020,A1

36
[ 175278-11-2 ]
2-(7-fluoro-3-(2-fluoropropan-2-yl)chroman-5-yl)-2-((R)-3-(4-(4-methoxy-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy)pyrrolidin-1-yl)acetic acid [ No CAS ]

Reference： [1]Patent: WO2020/47207,2020,A1

37
[ 1458-98-6 ]
[ 175278-11-2 ]
1-bromo-3,5-difluoro-2-(2-methylallyl)benzene [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
69%		To a cooled solution of l-<strong>[175278-11-2]bromo-3,5-difluoro-2-iodobenzene</strong> (3.00 g, 9.41 mmol) in THF (15 mL, 0.63 M) at -20 C was added a solution of iPrMgCl (2M in THF, 6.12 mL, 12.23 mmol) dropwise. The mixture was stirred for 10 min and then warmed to 0 C and stirred an additional 50 min. Copper iodide (0.448 g, 2.35 mmol) was added, and the reaction was stirred for 10 min. 3-bromo-2-methylprop-l-ene (1.04 mL, 10.4 mmol) was added, and the mixture was warmed to room temperature and stirred overnight. The reaction was quenched with sat. aq. NH4C1 (20 mL), diluted with EtOAc (20 mL) and extracted with EtOAc (3 x 10 mL). The combined organics were washed with brine (2 x 20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The resulting residue was purified by silica gel column (100% Hex) to give the desired product l-bromo-3,5- difluoro-2-(2-methylallyl)benzene as a colorless and clear oil (1.60 g). Yield 69%.

Reference： [1]Patent: WO2020/47207,2020,A1 .Location in patent: Page/Page column 115-116

38
[ 175278-11-2 ]
[ 17435-72-2 ]
ethyl 2-(2-bromo-4,6-difluorobenzyl)acrylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
> 95%		To a cooled solution of l-<strong>[175278-11-2]bromo-3,5-difluoro-2-iodobenzene</strong> (10.0 g, 31.4 mmol) in THF (25 mL, 1.3 M) at -20 C was added a solution of iPrMgCl (2M in THF, 20.4 mL, 40.8 mmol) dropwise. The mixture was stirred for 10 min and then warmed to 0 C and stirred an additional 50 min. Copper iodide (1.49 g, 7.84 mmol) was added, and the mixture was stirred for 10 min. Ethyl 2-(bromomethyl)acrylate (6.36 g, 4.55 mL, 32.9 mmol) was added, and the mixture was warmed to room temperature and stirred overnight. The reaction was quenched with sat. aq. NH4C1 (25 mL), diluted with EtOAc (25 mL) and extracted with EtOAc (3 x 30 mL). The combined organics were washed with brine (4 x 50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The resulting residue was purified by silica gel column to give the desired product l-bromo- 3,5-difluoro-2-(2-methylallyl)benzene as a colorless and clear oil (10 g). Yield >95%.

Reference： [1]Patent: WO2020/47207,2020,A1 .Location in patent: Page/Page column 127

39
tert-butyl (2S)-2-(oxiran-2-yl)pyrrolidine-1-carboxylate [ No CAS ]
[ 175278-11-2 ]
tert-butyl (2S)-2-(2-(2-bromo-4,6-difluorophenyl)-1-hydroxyethyl)pyrrolidine-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
118 g		At -70C, under a nitrogen atmosphere, /PrMgCI (190 ml_, 2.0 M in THF, 102.8 mmol) was added dropwise over 30 min to a solution of 1 -bromo-3,5-difluoro-2-iodobenzene (120.5 g, 377.9 mmol) in THF (800 ml.) while maintaining an internal temperature at -40C to -35C. The reaction mixture was stirred at -this temperature for 1 h. Upon completion of the reaction Cul (11.1 g, 58.1 mmol) was added quickly in one portion. A solution of tert-butyl (2S)-2-(oxiran-2-yl)pyrrolidine-1- carboxylate (C-XXXIV-k) (62 g, 290.7 mmol) in THF (100 ml.) was added dropwise over 10 min while maintaining the internal temperature at -40C to -30C. The reaction mixture was then gradually warmed to RT and stirred overnight. 20 wt% aq. NH CI (700 ml.) was added carefully to quench the reaction followed by MTBE (400 ml_). The organic layer was separated and the water layer was extracted with MTBE (200 ml_). The combined organic layers were washed with 20 wt% brine (300 ml_), dried over anhydrous Na2SC>4, filtered and concentrated to give the title product (118 g) as a pale yellow oil which was used directly in the next step. 1H NMR (400 MHz, CDCh) d 7.13 (dt, J= 8.1 , 2.2 Hz, 1 H), 6.80 (td, J= 9.1 , 2.6 Hz, 1 H), 4.63 (s, 1 H), 4.04 - 3.94 (m, 1 H), 3.86 - 3.72 (m, 1 H), 3.58 - 3.44 (m, 1 H), 3.41 - 3.28 (m, 1 H), 3.01 - 2.78 (m, 2H), 2.14 - 1.81 (m, 4H), 1.47 (s, 9H). UPLC-MS 5: HRMS m/z calcd for Ci Hi5BrF2NO [M-Boc]+ 306.0300, found 306.0292.

Reference： [1]Patent: WO2021/186324,2021,A1 .Location in patent: Page/Page column 183-184

40
[ 175278-11-2 ]
(2-bromo-4,6-difluorophenyl)methanol [ No CAS ]